BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19665226)

  • 1. Epigenetic modifications in AML and MDS.
    Mahmud M; Stebbing J
    Leuk Res; 2010 Feb; 34(2):139-40. PubMed ID: 19665226
    [No Abstract]   [Full Text] [Related]  

  • 2. Epigenetic changes in therapy-related MDS/AML.
    Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
    Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
    Benetatos L; Dasoula A; Hatzimichael E; Syed N; Voukelatou M; Dranitsaris G; Bourantas KL; Crook T
    Ann Hematol; 2011 Sep; 90(9):1037-45. PubMed ID: 21340720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiology of leukemia and MDS among atomic bomb survivors in Hiroshima and Nagasaki suggests how abnormal epigenetic regulation contributes to leukemogenesis].
    Inaba T
    Rinsho Ketsueki; 2009 Oct; 50(10):1548-52. PubMed ID: 19915365
    [No Abstract]   [Full Text] [Related]  

  • 5. [Methylation status of LINE-1 sequences in patients with MDS or secondary AML].
    Römermann D; Hasemeier B; Metzig K; Schlegelberger B; Länger F; Kreipe H; Lehmann U
    Verh Dtsch Ges Pathol; 2007; 91():338-42. PubMed ID: 18314632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction.
    Baylin SB; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S1-3. PubMed ID: 16341235
    [No Abstract]   [Full Text] [Related]  

  • 7. Epigenetic signatures as prognostic tools in acute myeloid leukemia and myelodysplastic syndromes.
    Christopeit M; Bartholdy B
    Epigenomics; 2014; 6(4):371-4. PubMed ID: 25333846
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P
    Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-quantitative study of calcitonin gene methylation in myelodysplastic syndrome.
    Wu S; Xie G; Bai R; Wang Y; Zhu P
    Chin Med J (Engl); 1998 Aug; 111(8):690-3. PubMed ID: 11245020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes.
    Chen H; Wu S
    Chin Med J (Engl); 2002 Jul; 115(7):987-90. PubMed ID: 12150726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epigenetic dysregulation in myelodysplastic syndrome].
    Sashida G; Iwama A
    Rinsho Ketsueki; 2015 Feb; 56(2):111-8. PubMed ID: 25765789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.
    Zhang Y; Zhang M; Yang L; Xiao Z
    Leuk Res; 2007 Jan; 31(1):109-11. PubMed ID: 16678898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q.
    Treppendahl MB; Möllgård L; Hellström-Lindberg E; Cloos P; Grønbaek K
    Eur J Haematol; 2013 Mar; 90(3):259-60. PubMed ID: 23190153
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetic and epigenetic alterations in myelodysplastic syndrome.
    Mihara K; Takihara Y; Kimura A
    Cytogenet Genome Res; 2007; 118(2-4):297-303. PubMed ID: 18000383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
    Harada H
    Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
    [No Abstract]   [Full Text] [Related]  

  • 18. [Study of nucleophosmin (NPM) gene mutation in patients with acute myeloid leukemia and myelodysplastic syndromes].
    Zhang Y; Zhang MR; Yang L; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):470-3. PubMed ID: 17147251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetics in AML.
    Melnick AM
    Best Pract Res Clin Haematol; 2010 Dec; 23(4):463-8. PubMed ID: 21130408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.
    Karlic H; Herrmann H; Varga F; Thaler R; Reitermaier R; Spitzer S; Ghanim V; Blatt K; Sperr WR; Valent P; Pfeilstöcker M
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):1-16. PubMed ID: 24183913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.